Repository logo
 
Publication

Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms

dc.contributor.authorMonteiro, Inês-de-Paula
dc.contributor.authorCalifano, Raffaele
dc.contributor.authorMountzios, Giannis
dc.contributor.authorde Mello, Ramon Andrade
dc.date.accessioned2017-04-07T15:57:38Z
dc.date.available2017-04-07T15:57:38Z
dc.date.issued2016
dc.description.abstractDespite recent advances, prognosis of patients with advanced lung cancer remains dismal. Owing to a better understanding of the interactions between immune system and tumor cells, immunotherapy has emerged as a promising therapeutic strategy. After the recent approval of nivolumab and the promising results with other immune checkpoint inhibitors, combination strategies are now subject of intensive research. Notwithstanding these successes, immunotherapy still holds significant drawbacks. As the target shifts from tumor cells to the tumor microenvironment, treatment paradigms are changing and several improvements are needed for optimal use in clinical practice. Robust biomarkers for patient selection and a reliable way of evaluating treatment response are high priorities. Herein we review current data on immune checkpoint inhibitors for lung cancer treatment.
dc.identifier.doi10.2217/fon.15.309
dc.identifier.issn1479-6694
dc.identifier.urihttp://hdl.handle.net/10400.1/9775
dc.language.isoeng
dc.peerreviewedyes
dc.relation.isbasedonWOS:000369525700014
dc.titleImmunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage564
oaire.citation.issue4
oaire.citation.startPage551
oaire.citation.titleFuture Oncology
oaire.citation.volume12
rcaap.rightsrestrictedAccess
rcaap.typearticle

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
H.9775.pdf
Size:
2.45 MB
Format:
Adobe Portable Document Format